Cancer

This is a phase 1b study to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT) and recommended phase 2 dose of APTO-253 HCl in patients with relapsed or refractory hematologic malignancies.

Primary disease category: 

This study is for the treatment of advanced solid tumors.

Primary disease category: 
Secondary disease category(ies): 

The aim of the study is to test the potential benefit of the addition of adjuvant chemotherapy following completion of primary chemoradiation for patients with locally advanced cervical cancer.

Primary disease category: 

This randomized phase III trial is studying radiation therapy to see how well it works compared with radiation therapy given together with cetuximab in treating patients who have undergone surgery for locally advanced head and neck cancer.

Primary disease category: 
Secondary disease category(ies): 

Pages

Subscribe to RSS - Cancer